Metronidazole Braun (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced to reactive nitro radical anions. These anions bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, which ultimately kills the bacteria or protozoa while sparing aerobic cells.

The dosage of Metronidazole Braun is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. No fixed regimen is provided here; the prescriber sets the appropriate dose.

Safety data for metronidazole in pregnancy are limited, and the drug is generally classified as a category B or C agent depending on the region. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as metronidazole is excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Metronidazole is often preferred for anaerobic infections because of its excellent tissue penetration and activity against a broad spectrum of obligate anaerobes. Compared with clindamycin, it has a lower risk of causing Clostridioides difficile colitis, while offering similar efficacy for many intra‑abdominal and gynecologic infections.

Metronidazole Braun should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze the product, and keep it in the original packaging to maintain stability. Once removed from refrigeration, use according to the manufacturer’s recommended time frame.

Metronidazole Braun is given by intravenous injection or infusion. The solution is typically diluted in compatible IV fluids and administered over a period specified by the prescriber, often 30‑60 minutes for a single dose. Administration should be performed by qualified healthcare personnel.

Serious adverse reactions include seizures, peripheral neuropathy, severe allergic responses such as anaphylaxis, Stevens‑Johnson syndrome, and significant liver injury. Patients should be monitored for neurological symptoms, skin reactions, and hepatic dysfunction, and treatment should be discontinued if any of these occur.

Metronidazole Braun is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazoles, and in patients with severe hepatic impairment. Caution is also advised for those with a history of seizures or peripheral neuropathy, and it should be avoided in patients who cannot abstain from alcohol during therapy.